Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M001229200 on June 19, 2000

J. Biol. Chem., Vol. 275, Issue 40, 31155-31161, October 6, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/40/31155    most recent
M001229200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsumoto, M.
Right arrow Articles by Tsujimoto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumoto, M.
Right arrow Articles by Tsujimoto, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-kappa B Ligand (RANKL)*

Masahito MatsumotoDagger, Tatsuhiko Sudo§, Tamio Saito, Hiroyuki Osada§, and Masafumi Tsujimoto

From the Laboratories of Cellular Biochemistry and § Antibiotics, RIKEN (The Institute of Physical and Chemical Research), 2-1 Hirosawa, Wako, Saitama, 351-0198 Japan

Received for publication, February 11, 2000, and in revised form, June 13, 2000

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The receptor activator of NF-kappa B ligand (RANKL) induces osteoclast differentiation from bone marrow cells in the presence of macrophage colony-stimulating factor. We found that treatment of bone marrow cells with SB203580 inhibited osteoclast differentiation via inhibition of the RANKL-mediated signaling pathway. To elucidate the role of p38 mitogen-activated protein (MAP) kinase pathway in osteoclastogenesis, we employed RAW264 cells which could differentiate into osteoclast-like cells following treatment with RANKL. In a dose-dependent manner, SB203580 but not PD98059, inhibited RANKL-induced differentiation. Among three MAP kinase families tested, this inhibition profile coincided only with the activation of p38 MAP kinase. Expression in RAW264 cells of the dominant negative form of either p38alpha MAP kinase or MAP kinase kinase (MKK) 6 significantly inhibited RANKL-induced differentiation of the cells. These results indicate that activation of the p38 MAP kinase pathway plays an important role in RANKL-induced osteoclast differentiation of precursor bone marrow cells.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Bone morphogenesis, remodeling, and resorption are controlled in part by osteoclasts. These cells differentiate from hematopoietic myeloid precursors of monocyte/macrophage lineage under control of osteotropic hormones and local factors produced by supporting cells such as osteoblasts and stromal cells (1-9).

The receptor activator of NF-kappa B ligand (RANKL)1 (10), also refereed to as osteoclast differentiation factor (11), tumor necrosis factor-related activation-induced cytokine (12), or osteoprotegerin ligand (13), was shown to be highly expressed in supporting cells and to directly induce the differentiation and maturation of osteoclasts (7, 13-15). To describe RANKL-induced osteoclastogenesis, the sequential phenotype progression model was proposed. The model includes the appearance of mononuclear osteoclasts, the fusion process prior to multinucleated osteoclast formation, and the osteoclast maturation process (6). Moreover, it has been shown that mutant mice disrupted with either RANKL or its receptor RANK revealed severe osteopetrosis and osteoclast defects (16, 17), indicating that the RANKL-RANK signaling system plays an essential role in osteoclast differentiation.

It has been shown recently that RANK is associated with tumor necrosis factor receptor-associated factors (TRAFs) (18-21). The intracellular domain of RANK contains two distinct TRAF-binding domains, each of which recognizes different TRAF proteins specifically (18, 19). While the C-terminal region of RANK interacts with TRAF2 and TRAF5, the TRAF6-binding domain resides in the middle of the RANK intracellular region. Overexpression of RANK C-terminal deletion mutants has revealed that activation of the RANK-mediated signaling pathway results in the activation of NF-kappa B and c-Jun N-terminal kinase (JNK) which correlate with the TRAF6 interaction activity of mutants (18, 19). In addition, mice with disrupted TRAF6 gene exhibit an osteopetrotic phenotype due to a defect in bone resorption (22, 23). Therefore it is speculated that JNK might play an important role in osteoclast differentiation.

Mitogen-activated protein (MAP) kinases are proline-directed serine/threonine kinases that are important in cell growth, differentiation, and apoptosis (24-27). They become activated by phosphorylation on threonine and tyrosine in response to external stimuli. Three major subfamilies of MAP kinase have been identified in mammalian cells: 1) extracellular signal regulated kinases (ERKs), 2) JNKs, and 3) p38 MAP kinases. It is widely accepted that peptide growth factors and phorbol esters preferentially activate ERKs, while cellular stresses, such as hyperosmolarity or reactive oxygen species, potently activate JNKs and p38 MAP kinases (28-30).

In this paper, we have investigated the possible involvement of MAP kinase families in the RANKL-RANK signaling pathway that leads to osteoclast differentiation. Here we demonstrate that a p38 MAP kinase inhibitor, SB203580, inhibits RANKL-induced osteoclast differentiation. In addition, we show that the expression of a dominant negative form of either p38 MAP kinase or MAP kinase kinase (MKK) 6 partially inhibits differentiation. Our results indicate for the first time that activation of the p38 MAP kinase pathway plays a role in RANKL-induced osteoclast differentiation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- Bone marrow cells were prepared by removing femurs from 6-8-week-old ddY mice and flushing the bone marrow cavity with RPMI 1640 (Life Technologies Inc., Gaithersburg, MD) containing 10% fetal bovine serum (JRH Biosciences, Lenexa, KS), 100 µg/ml kanamycin, 1% non-essential amino acid (NEAA), 1% sodium pyruvate, and 5 µM beta -mercaptoethanol. After lysing erythrocytes with a lysing buffer (17 mM Tris, pH 7.65, 0.75% NH4Cl), cells were seeded at 1.5 × 106 cells/well (0.5 ml) in 24-well plates in the presence of human recombinant soluble RANKL (sRANKL, Peprotech EC Ltd., London, United Kingdom) and/or murine M-CSF (Genzyme, Cambridge, MA). The culture medium was replaced every 3 days with a fresh complete medium containing the appropriate reagents. After 8-10 days, cells were washed and subjected to a tartrate-resistant acid phosphatase (TRAP) assay (see below). RAW264 (RIKEN, RCB0535 lot number 008) were grown in minimal essential medium supplemented with 5% fetal bovine serum and 1% NEAA. For the TRAP assay, RAW264 cells were trypsinized and starved for 5 h in serum-free minimal essential medium/NEAA media and then cultured for 5 days in MEM/NEAA containing 2% fetal bovine serum and sRANKL.

Materials-- Polyclonal antibodies against p38 MAP kinase, phosphorylated p38 MAP kinase (Thr180/Tyr182), JNKs (p46 and p54), and phosphorylated JNKs (Thr183/Tyr185) were purchased from New England BioLabs Inc. (Beverly, MA). Monoclonal anti-phosphorylated p42/44 MAP kinase (ERKs) (Thr202/Tyr204) antibody was also from New England BioLabs. The polyclonal anti-MAPKAP kinase-2 and MAPKAP kinase substrate peptide were obtained from Upstate Biotechnology Inc. (Lake Placid, NY). Recombinant mouse osteoprotegerin (OPG)-Fc chimera and polyclonal anti-RANK antibody were from R & D Systems Inc. (Minneapolis, MN). The p38 MAP kinase expression plasmid was prepared as described previously (31). The MKK6 expression plasmid was a kind gift provided by Dr. H. Sakurai (Tanabe pharmaceutical Co., Ltd., Osaka, Japan). The p38 MAP kinase or MKK6 cDNAs were cloned into the retroviral vector pLNCX2 plasmid vector (CLONTECH, Palo Alto, CA) and designated pLNCX38 and pLNCXMKK6, respectively. Dominant negative mutant expression plasmids of p38 MAP kinase and MKK6 were generated, respectively, from pLNCX38 and pLNCXMKK6 via PCR primed by oligonucleotides 5'-GATGATGAGATGGCAGGCTGCGTGGCTACCAGG-3' and 5'-CCTGGTAGCCACGCAGCCTGCGATCTCATCATC-3' for the p38 dominant negative form, and 5'-AGCGGGCAGATCATGGCAGTGGCGCGGATCCGAGCCACAGTAAAT-3' and 5'-ATTTACTGTGGCTCGGATCCGCGCCACTGCCATGATCTGCCCGCT-3' for the MKK6 dominant negative form. The Thr180-Gly-Tyr182 motif was replaced by Ala180-Gly-Phe182, using a Quick-ChangeTM site-directed mutagenesis kit (Stratagene, La Jolla, CA). The sequences of these cDNA constructs were confirmed by DNA sequencing on both strands. SB203580 and PD98059 were purchased from Calbiochem Corp. (La Jolla, CA) and New England Biolabs, respectively.

Osteoclast Differentiation Assay-- Osteoclast formation was measured by quantifying TRAP-positive cells (32). In brief, adherent cells were fixed with 10% formaldehyde in phosphate-buffered saline for 3 min. After treatment with ethanol/acetone (50:50 v/v) for 1 min, the cell surface was air dried and incubated for 10 min at room temperature in an acetate buffer (0.1 M sodium acetate, pH 5.0) containing 0.01% naphthol AS-MX phosphate (Sigma) and 0.03% fast red violet LB salt (Sigma) in the presence of 50 mM sodium tartrate. Osteoclast-like TRAP-positive cells in each well were scored by counting the number of TRAP-positive mononuclear or multinucleated cells containing three or more nuclei. Except otherwise stated, results of the number of TRAP-positive cells derived from RAW 264 cells were expressed as percent TRAP-positive cells because of the large number of the cells in culture.

Detection of mRNA Expression by Reverse Transcription-Polymerase Chain Reaction (RT-PCR)-- Total RNA for cDNA synthesis was isolated from murine bone marrow cells by the guanidine-thiocyanate method as described (33). RNA was reverse-transcribed using Superscript II reverse transcriptase (Life Technologies, Grand Island, NY), 1 mM dNTPs, 1 µg of oligo(dT) primers, and the supplied buffer. RT-PCR assays were carried out using the following primer pairs for TRAP, RANK (34), and beta -actin (32) as described: TRAP, 5'-CAATGACAAGAGGTTCCAGGAGACCT-3' (sense) and 5'-ACAGGTAGGCGGTGACCCCGTATG-3' (antisense). PCRs for TRAP, RANK, and beta -actin were carried out for 1 cycle at 95 °C for 9 min, followed by 25 cycles at 94 °C for 0.5 min, at 54 °C for 1 min, and at 72 °C for 1 min.

Western Blot Analysis-- Immunoblots and immunoprecipitations were performed as described (35). In brief, cells were lysed in a lysis buffer (20 mM Hepes, pH 7.4, 2 mM EGTA, 50 mM beta -glycerophosphate, 0.1% Triton X-100, 10% glycerol, 1 mM dithiothreitol, 1 µg/ml leupeptin, 5 µg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate). Whole cell extracts were prepared by centrifugation at 10,000 × g for 15 min at 4 °C. Whole cell extracts (30 µg) were electrophoresed on a 10% SDS-polyacrylamide gel and blotted onto polyvinylidene difluoride membranes. Immunoblot detection was performed with the corresponding rabbit antiserum or mouse monoclonal antibody using a ECL detection kit (Amersham Pharmacia Biotech, Buckinghamshire, UK).

Protein Kinase Assays-- p38 MAP kinase and JNK activities were measured in an immune complex kinase assay. Phosphorylated p38 MAP kinase was immunoprecipitated by incubation with anti-phosphorylated p38 (pp38) monoclonal antibody immobilized on agarose beads (anti-pp38 Ab-agarose), and phosphorylated JNK with GST-c-Jun fusion protein bound to glutathione-Sepharose beads (GST-c-Jun-Sepharose). After 16 h of incubation at 4 °C, the immunoprecipitates were collected, washed twice with whole cell extract lysis buffer, and then twice with a kinase buffer (25 mM Tris, pH 7.5, 5 mM beta -glycerophosphate, 2 mM dithiothreitol, 0.1 mM sodium orthovanadate, 10 mM MgCl2). Immunoprecipitates of anti-pp38 Ab-agarose were mixed with 2 µg of GST fused to ATF2 (GST-ATF2) protein as a substrate and 200 µM ATP in 50 µl of kinase buffer. Pellets precipitated with GST-c-Jun-Sepharose were mixed with 100 µM ATP in 50 µl of kinase buffer. Then the reaction mixtures were further incubated for 30 min at 30 °C. The kinase reaction was terminated by boiling in an appropriate volume of SDS sample buffer. The phosphorylated GST-ATF2 and GST-c-Jun-(1-89) proteins were detected by Western blot analyses with anti-phosphorylated ATF2 polyclonal and anti-phosphorylated c-Jun polyclonal antibodies (New England Biolabs), respectively.

For MAPKAP kinase-2 assay, immunoprecipitates were incubated for 30 mim at 30 °C with 100 µM ATP and 1 µCi of [gamma -32P]ATP in 30 µl of the kinase buffer (50 mM beta -glycerophosphate, pH 7.0, 0, 1 mM EDTA, 10 mM magnesium acetate, and 0.1 mM Na3VO4). The reactions were terminated by adding 10 µl of 1% orthophosphoric acid containing 1 mM ATP and 1% bovine serum albumin. An aliquot (25 µl) was then spotted onto P81 phosphocellulose filters and radioactivity incorporated into the substrate peptide was determined by liquid scintillation spectrometry after washing the filter five times in 0.75% phosphoric acid.

Preparation of High Titier Retroviral Particles and Infection-- Ecopack 293 packaging cells (CLONTECH) were cultured in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% fetal calf serum and 100 µg/ml kanamycin. Cells to be transfected were plated 24 h before transfection at a density of 2 × 106 cells per 100-mm dish. Using a calcium phosphate precipitation protocol, Ecopack 293 cells were co-transfected with expression plasmids and pVSV-G (as an envelope to infect RAW264 cells) which was a kind gift from Dr. H. Miyoshi (The Salk Institute). Supernatants from the transfected 293 cells were collected 72 h after transfection and concentrated by centrifugation (8,000 × g). High titer virus particles were used for infection to target cells after filtration through 0.45-µm filters. Transformants were selected in cultures supplemented with the appropriate concentration of G418.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Characterization of Osteoclast Differentiation from Bone Marrow Cells Induced by M-CSF and sRANKL-- It is well known that the treatment of bone marrow cells with M-CSF and RANKL induces osteoclast differentiation (6, 10-15). Fig. 1A shows the typical morphological changes of murine bone marrow cell-derived adherent cells into TRAP-positive cells when treated with these cytokines. Treatment of the cells with M-CSF alone resulted in an increase in the number of surviving cells compared with control cells (Fig. 1A, b). However, no TRAP-positive cells were observed in the culture. In contrast, sRANKL induced the appearance of TRAP-positive mononuclear cells without increase in the number of adherent cells (Fig. 1A, d). In the presence of M-CSF and sRANKL, drastic morphological changes of adherent cells were observed and TRAP-positive mononuclear and multinucleated cells appeared in the culture (Fig. 1A, c).


View larger version (74K):
[in this window]
[in a new window]
  		Fig. 1.   RANKL-induced formation of osteoclast-like multinucleated cells from murine bone marrow cells. A, bone marrow cells were incubated for 8 days with: no addition (a), M-CSF (20 ng/ml) (b), M-CSF (20 ng/ml) and sRANKL (50 ng/ml) (c), sRANKL (50 ng/ml) (d), M-CSF (20 ng/ml), sRANKL (50 ng/ml), and SB203580 (10 µM) (e), or M-CSF (20 ng/ml), sRANKL (50 ng/ml), and PD98059 (20 µM) (f). The cells were treated with inhibitors 30 min prior to the addition of cytokines. After incubation, cells were subjected to the TRAP assay as described under "Experimental Procedures." Scale bar = 100 µm. B, quantitative analysis of bone marrow cell differentiation. The number of TRAP-positive multinucleated cells containing three or more nuclei were scored. Results represent the mean ± S.D. of triplicate determinations. Similar results were obtained in three independent experiments.

To determine the possible involvement of MAP kinase signaling pathways in RANKL-induced bone marrow cell differentiation into TRAP-positive cells, bone marrow cells were treated with SB203580, a specific inhibitor of p38 MAP kinase (28, 29, 36, 37). As shown in Fig. 1A, part e, treatment of bone marrow cells with SB203580 inhibited the appearance of both TRAP-positive mononuclear and multinucleated cells almost completely. However, it should be noted that an increase in the number of intact cells was observed, suggesting that SB203580 did not affect the proliferation stage mediated by M-CSF. In contrast, treatment with PD98059, a specific inhibitor of MAPK/ERK kinase, had no effect on the differentiation of the cells (Fig. 1A, f). Fig. 1B summarizes the effects of the inhibitors on ostroclast differentiation induced by the cytokines.

To examine the effects of SB203580 on the expression of TRAP and sRANK mRNAs in bone marrow cell-derived adherent cells stimulated with M-CSF and RANKL, RT-PCR was first performed. We found that while treatment of SB203580 caused the decrease in the expression level of TRAP mRNA, expression of RANK mRNA was observed, suggesting that SB203580 did not exert its differentiation inhibition activity via decreasing in the RANK mRNA expression level (data not shown). The effect of SB203580 on the expression of RANK at the protein level was examined by Western blot analysis (Fig. 2). As expected, treatment with M-CSF and sRANKL caused the enhancement of RANK expression (lane 2) (34). Both SB203580 and PD98059 had no significant effects on the expression of RANK proteins induced by the cytokines (lanes 3 and 4).


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 2.   Western blot analysis of RANK expressed in bone marrow cells. Cells treated with M-CSF (20 ng/ml) and sRANKL (50 ng/ml) in the presence or absence of inhibitors were incubated for 8 days and subjected to the analysis as described under "Experimental Procedures." Control cells were harvested without cytokine treatment at day 0.

To confirm that SB203580 interferes with the RANKL-mediated signal transduction system, bone marrow cells were treated sequentially with M-CSF and sRANKL (Fig. 3). To this end the cells were treated with M-CSF in the presence or absence of SB203580 and incubated for 3 days. After removing the reagents by washing, cells were further incubated for 2 days with the indicated reagents. Sequential treatment with M-CSF and sRANKL without SB203580 resulted in the appearance of TRAP-positive mononuclear cells. When cells were pretreated with M-CSF and then incubated in the presence of sRANKL and SB203580, few TRAP-positive mononuclear cells were observed. In contrast, after treatment with M-CSF and SB203580, sRANKL induced the appearance of TRAP-positive cells, indicating that SB203580 interfered with sRANKL-mediated, but not M-CSF-mediated, signaling pathways. Taken together, the results described above strongly suggest that activation of the p38 MAP kinase signaling pathway is involved in the RANKL-induced differentiation of bone marrow cells into osteoclasts.


View larger version (13K):
[in this window]
[in a new window]
  		Fig. 3.   Sequential treatment of bone marrow cells with M-CSF and sRANKL. Bone marrow cells were precultured with 20 ng/ml M-CSF for 3 days in the presence or absence of 10 µM SB203580. After washing with phosphate-buffered saline, cells were further incubated for 2 days with either M-CSF or sRANKL as indicated in the figure. As a control, bone marrow cells were incubated without cytokine treatment. Results represent the mean ± S.D. of triplicate determinations.

SB203580 Inhibits the RANKL-induced Differentiation of RAW264 Cells-- To further examine the role of action of p38 MAP kinase in sRANKL-mediated osteoclast differentiation, we employed the murine monocyte cell line, RAW264, to simplify the assay system, since this cell line is known to express RANK and differentiate into TRAP-positive cells when co-cultured with bone slices and sRANKL (18) (Fig. 4A). Interestingly, treatment with sRANKL alone caused the induction of TRAP-positive mononuclear and multinucleated cells (Fig. 4A, c), whereas M-CSF had no effect on the cells as judged by cell number and morphology (Fig. 4A, b). The effect of sRANKL was first detectable at a concentration of 5 ng/ml and reached a maximum level at 50 ng/ml (Fig. 4B). SB203580 inhibited the appearance of TRAP-positive cells in a dose-dependent manner with IC50 being 0.56 µM (Fig. 4C).


View larger version (41K):
[in this window]
[in a new window]
  		Fig. 4.   Inhibition of sRANKL-induced RAW264 cell differentiation by SB203580. A, RAW264 cells were seeded at 1 × 104 cells per well in 96-well plates and incubated for 5 days with: no addition (a), M-CSF (20 ng/ml) (b), sRANKL (50 ng/ml) (c), sRANKL (50 ng/ml) and SB203580 (10 µM) (d), or sRANKL (50 ng/ml) and PD98059 (20 µM) (e). After incubation, cells were subjected to the TRAP assay as described under "Experimental Procedures." Scale bar = 50 µm. B, quantitative analysis of the differentiation of RAW264 cells into TRAP-positive cells. The cells were incubated with various concentrations of sRANKL in the presence or absence of inhibitors as indicated. C, effects of SB203580 and PD98059 on the differentiation of RAW264 cells. RAW264 cells were treated with 50 ng/ml sRANKL in the presence of various concentrations of SB203580 (closed circle) or PD98059 (open circle) and TRAP-positive cells were counted. Results represent the mean ± S.D. of triplicate determinations.

Activation of MAP Kinases by sRANKL-- We next examined whether or not p38 MAP kinase was indeed activated by sRANKL in RAW264 cells (Fig. 5). Activation of p38 MAP kinase was monitored by an immunoblot analysis employing the anti-pp38 MAP kinase antibody. Kinetic analysis revealed phosphorylated p38 MAP kinase to be detectable within 5 min, reached a plateau at 15 min after addition of sRANKL, and gradually declined to a basal level in up to 2 h. In contrast, total amounts of p38 MAP kinase protein were not affected by sRANKL treatment as shown by the anti-p38 MAP kinase antibody. We also measured the in vitro kinase activity employing the GST-ATF2 fusion protein as a substrate and found that the phosphorylation of p38 MAP kinase correlated well with the kinase activity (data not shown).


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 5.   Activation of p38 MAP kinase in RAW264 cells treated with sRANKL. RAW264 cells (106 cells/culture) were treated with 50 ng/ml sRANKL for the indicated times and then cells were lysed. Cell lysates (30 µg) were resolved by SDS-PAGE and immunoblotted with anti-pp38 MAP kinase (upper panel) or anti-p38 MAP kinase antibody (lower panel). As a control, the effect of M-CSF (20 ng/ml) on the phosphorylation of p38 MAP kinase is also shown.

To confirm the in vivo activation of p38 MAP kinase, we next measured the activation of MAPKAP kinase-2, a downstream substrate of p38 MAP kinase and its inhibition by SB203580 (38). Activation of MAPKAP kinase-2 in RAW264 cells was first observed at 15 min and reached to the maximum level at 60 min after addition of sRANKL (Fig. 6A). Pretreatment of the cells with SB203580 inhibited the RANKL stimulated activity of MAPKAP kinase-2 in a dose-dependent manner with IC50 being 0.43 µM SB203580, indicating that SB203580 inhibits MAPKAP kinase-2 with a similar IC50 to that which inhibits osteoclast differentiation (Fig. 6B).


View larger version (15K):
[in this window]
[in a new window]
  		Fig. 6.   Activation of MAPKAP kinase-2 in RAW264 cells treated with sRANKL. A, RAW264 cells were treated with sRANKL (50 ng/ml) for the indicated times in the presence (closed circle) or absence (open circle) of 5 µM SB203580. Cell lysates were then immunoprecipitated with anti-MAPKAP kinase-2 antibody followed by the kinase reaction. The MAPKAP kinase-2 activity was determined by measuring radioactivity of incorporated into MAPKAP kinase-2 substrate peptide (see "Experimental Procedures"). B, inhibition of MAPKAP kinase-2 activity by SB203580. RAW264 cells were pretreated with various concentrations of SB203580 for 30 min. Cells were then treated with 50 ng/ml sRANKL, further incubated for 15 min, and immunoprecipitated with anti-MAPKAP kinase-2 antibody. C, inhibition of MAPKAP kinase-2 activity by OPG. RAW264 cells were treated with 50 ng/ml sRANKL in the presence of various concentrations of OPG for 15 min and immunoprecipitated with anti-MAPKAP kinase-2 antibody. Results represent the mean ± S.D. of triplicate determinations.

Since OPG is a decoy receptor for RANK and inhibits the RANKL-induced osteoclastogenesis (39, 40), we next examined the effect of OPG on RANKL-induced activation of p38 MAP kinase. As shown in Fig. 6C, in the presence of 50 ng/ml RANKL, 3-fold increase in the MAPKAP kinase-2 activity was observed. OPG inhibited the MAPKAP kinase-2 activity in a dose-dependent manner, further supporting the role of p38 MAP kinase in osteoclastogenesis.

Since RANKL is known to activate JNK (18-20, 22), we also measured the sRANKL-induced JNK activation in RAW264 cells (Fig. 7A). Treatment with sRANKL for time periods ranging from 5 to 15 min increased phosphorylation of the 46- and 56-kDa isoforms of JNK. Phosphorylation levels of these JNK isoforms correlated to increased in vitro JNK kinase activity as measured using the GST-c-Jun fusion protein as a substrate. Both SB203580 and PD98059 had no effect on phosphorylation and kinase activity of JNK(s) (Fig. 7B).


View larger version (41K):
[in this window]
[in a new window]
  		Fig. 7.   sRANKL-induced activation of JNKs and ERKs. A, phosphorylation by sRANKL of p46 and p54 forms of JNK. RAW264 cells (106 cells/culture) were treated with 50 ng/ml sRANKL for the indicated periods of time, and the cells were lysed. Cell lysates were then subjected to Western blot analysis with a polyclonal antibody against phosphorylated JNKs (upper panel) or an anti-JNK polyclonal antibody (lower panel). To prevent a possible cross-talk between JNKs and p38 MAP kinases, SB203580 was included during the incubation period. B, effects of inhibitors on JNK activation induced by sRANKL. RAW264 cells were incubated with 50 ng/ml sRANKL for 15 min in the presence or absence of either SB203580 (10 µM) or PD98059 (20 µM). Cell lysates were precipitated with GST-c-Jun Sepharose. Precipitates were then assayed for its kinase activity employing GST-c-Jun-(1-89) as a substrate. Phosphorylated c-Jun was detected by Western blot analysis employing an anti-phosphorylated c-Jun polyclonal antibody. C, phosphorylation of p42 and p44 forms of ERK by sRANKL. RAW264 cells were incubated with 50 ng/ml sRANKL for 15 min in the presence or absence of either SB203580 (10 µM) or PD98059 (20 µM). Cell lysates were then subjected to Western blot analysis with the anti-phospho-p42/44 ERK monoclonal antibody.

We then measured the sRANKL-induced phosphorylation of the 42-/44-kDa ERKs in RAW264 cells (Fig. 7C). It appeared that treatment with sRANKL caused an increase in the phosphorylation level of both isoforms. PD98059 but not SB203580 inhibited the phosphorylation (and activation) of ERKs. These results suggest that although sRANKL can activate three major subfamilies of MAP kinase in RAW264 cells, only p38 MAP kinase activity is correlated with sRANKL-mediated differentiation of the cells.

Effects of Expression of Dominant Negative Forms of p38 MAP Kinase and MKK6-- In order to confirm the essential role of the p38 MAP kinase signaling pathway in sRANKL-induced RAW264 cell differentiation, the cells were introduced to an engineered retrovirus vector encoding the wild type (CX38 cell) or a dominant negative mutant (CX38DN cell) of p38alpha MAP kinase, and transformants were cloned. As a control, an empty vector (CX2 cell) was also introduced and cloned.

When CX38 cells were treated with sRANKL, a comparable level of TRAP-positive to CX2 cells appeared (Fig. 8A). In contrast, expression of the dominant negative form of p38alpha MAP kinase caused about 30% decrease in the appearance of TRAP-positive cells after treatment with sRANKL. It should be noted that the appearance of both TRAP-positive mononuclear and multinucleated cells was affected. Thus expression of the dominant negative form of p38alpha MAP kinase caused a significant decrease in the ability of cells to differentiate into TRAP-positive cells.


View larger version (15K):
[in this window]
[in a new window]
  		Fig. 8.   Effects of expression of dominant negative forms of p38 MAP kinase and MKK6. A, RAW264 cells were mock-transfected (CX2) or transfected with an expression vector encoding wild type p38 MAP kinase (CX38) or a dominant negative form of p38 MAP kinase (CX38DN). B, RAW264 cells were mock-transfected (CX2) or transfected with an expression vector encoding wild type MKK6 (CXMKK6) or a dominant negative form of MKK6 (CXMKK6DN) Transformants were incubated with various concentrations of sRANKL for 5 days. After incubation, the TRAP-positive cells were counted as described under "Experimental Procedures." Results represent the mean ± S.D. of triplicate determinations.

To further confirm the role of the p38 MAP kinase pathway, the cells were transfected with expression vectors encoding wild type MKK6 (CXMKK6 cell) or the dominant negative form of MKK6 (CXMKK6DN cell). As shown in Fig. 8B, about 50% decrease in the number of TRAP-positive cells induced by sRANKL was observed, indicating that a defect in the upstream regulator of p38 MAP kinase also caused the suppression of differentiation.

Fig. 9 shows the effects of the dominant negative forms of kinases on the activation of p38 MAP kinase. Treatment of CX2 cells with sRANKL caused a 3-fold increase in the p38 MAP kinase activity (by measuring the MAPKAP kinase-2 activity). Further increase in the activity of p38 MAP kinase was observed in CX38 and CXMKK6 cells (4.2- and 4.1-fold, respectively) after treatment with sRANKL. In contrast, while the expression of the dominant negative form of p38 MAP kinase caused 26% decrease in the sRANKL-mediated enhancement of MAPKAP kinase-2 activity in CX38DN cells, that of the dominant negative form of MKK6 caused 41% decrease in CXMKK6DN cells, indicating some correlation between the p38 MAP kinase activity and the differentiation of the cells. Although not quantitative, comparable results were obtained by measuring the phosphorylation of p38 MAP kinase (Fig. 9A).


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 9.   Expression of dominant negative forms of p38 MAP kinase and MKK6 caused the decrease in the p38 MAP kinase activity. Phosphorylation of p38 MAP kinase (A) and MAPKAP kinase-2 activity (B) were measured as described in the legends for Figs. 5 and 6, respectively. MAPKAP kinase-2 activity was measured in the presence (filled bar) or absence (open bar) of sRANKL. Results represent the mean ± S.D. of triplicate determinations.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Osteoclasts differentiate from hematopoietic precursors through interaction with stromal and osteoblast cells, which provide the microenvironment essential for osteoclastogenesis (1-7, 15, 16). One of the critical factors produced by these two supporting cells is M-CSF (41-44). In the presence of M-CSF, bone-resorbing factors such as prostaglandin E2 (45), vitamin D3 (1,25-(OH)2D3) (46), and parathyroid hormone (47), induce the differentiation of precursor cells to mononuclear osteoclasts, followed by the generation of multinucleated osteoclasts. It was reported that the differentiation inducing activity of these reagents was mediated by RANKL, since the addition of OPG/OCIF, a decoy receptor for RANK, completely inhibited the generation of osteoclasts (39, 40). These results suggest that in combination with M-CSF, RANKL plays an essential role in the induction of osteoclast differentiation.

In this paper, we have confirmed that both M-CSF and sRANKL are required to induce terminal differentiation of bone marrow cells into multinucleated osteoclasts. Our results suggest that M-CSF and RANKL act on bone marrow cells sequentially to induce the terminal differentiation to osteoclasts and that RANKL is the differentiation inducing factor in our assay system since sRANKL alone could induce the TRAP-positive mononulear cells in the absence of the increase in cell number. Several reports indicate that M-CSF plays an essential role in osteoclastogenesis through RANK induction, the stimulation of cell survival and proliferation, and by acting as a competence factor for differentiation (34, 48, 49).

It was quite unexpected for us that SB203580 but not PD98059 inhibited the M-CSF/sRANKL-induced differentiation of bone marrow cells into multinucleated osteoclasts. Since an increase in the number of adherent cells, albeit no appearance of TRAP-positive cells, was observed even in the presence of SB203580, we can speculate that SB203580 inhibits the differentiation of bone marrow cells by interfering with the RANKL-induced p38 MAP kinase activity.

To elucidate the causal link between the activation of the p38 MAP kinase pathway and RANKL-induced osteoclast differentiation, we employed RAW264 cells which expressed RANK and differentiated into TRAP-positive multinucleated cells through sRANKL treatment. As was the case with bone marrow cells, SB203580 but not PD98059 inhibited differentiation induced by sRANKL. In RAW264 cells, RANKL-induced activations of ERKs, JNKs, and p38 MAP kinase were clearly detected and SB203580 inhibited only the p38 MAP kinase activity. These results strongly suggest that at least in part p38 MAP kinase plays a critical role in RANKL-induced differentiation. However, we cannot rule out the possible involvement of ERK and JNK in osteoclastogenesis at present.

Expression of the dominant negative form of p38alpha MAP kinase resulted in a significant decrease in the number of TRAP-positive cells induced by RANKL. Significant decrease in the RANKL-induced p38 MAP kinase activation was also observed. These results further support the notion that the activation of the p38 MAP kinase signaling pathway is necessary for sRANKL-induced differentiation of bone marrow cells and RAW264 cells into osteoclasts. However, complete inhibition was not observed in CX38DN cells expressing the dominant negative form of p38alpha MAP kinase. It is conceivable that other isoforms of p38 MAP kinase could compensate for a possible defect in the signaling pathway through p38alpha MAP kinase. In addition to the alpha -type, at least three isoforms (beta -, gamma -, and delta -types) of p38 MAP kinase are reported (50-55). We detected the expression of the mRNA for beta -type in RAW264 cells by RT-PCR (data not shown). Therefore it is possible that p38beta MAP kinase functions in CX38DN cells. Because SB203580 inhibited osteoclastogenesis completely, it is likely that only p38alpha and p38beta MAP kinases are involved in differentiation since these are the only isoforms inhibited by SB203580 at the low doses (38).

MKK6 is a direct and specific activator of all p38 MAP kinase isoforms so far identified (56, 57). Expression of the dominant negative form of MKK6 inhibited both sRANKL-induced differentiation of RAW264 cells and p38 MAP kinase activation. It is likely that the dominant negative form of MKK6 inhibits both alpha - and beta -types of p38 MAP kinase, thus conferring a greater range of differentiation inhibition than the inhibition performed by the dominant negative form of p38alpha MAP kinase. The quantitative differences between the suppression of differentiation seen with dominant negative forms of p38alpha MAP kinase and MKK6 could be completely explained by the extent to which the transfected forms are able to suppress p38 activity in cells. Presumably if they were more efficient, they could both achieve complete suppression.

In conclusion, we have demonstrated in this paper that the p38 MAP kinase signaling pathway plays a crucial role in RANKL-mediated differentiation of bone marrow cells into osteoclasts. However, experiments of the overexpression of wild type kinases revealed no correlation between p38 MAP kinase activity and RANKL-induced differentiation, suggesting the role of other factors in the RANKL-mediated osteoclastogenesis. Since the activation of other MAP kinase families (i.e. ERKs and JNKs) during differentiation was clearly observed, the contribution of these kinases to osteoclast differentiation should be elucidated in the near future.

    ACKNOWLEDGEMENTS

We are grateful to Drs. Y. Tanaka, K. Ikenaka, I. Morishima, M. Muroi, and A. Takatsuki for helpful discussions and support. We also thank Dr. H. Sakurai for the MKK6 expression plasmids; and Dr. A. Hattori for critical reading of the manuscript.

    FOOTNOTES

* This work was supported in part by a grant from the "Multibioprobe Research Program" from RIKEN and a grant from TERUMO Life Science Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Special Riken Postdoctoral Researcher.

To whom correspondence should be addressed: Laboratory of Cellular Biochemistry, RIKEN, 2-1 Hirosawa, Wako-shi, Saitama-ken, 351-0198, Japan. Fax: 81-48-462-4670; E-mail: tsujimot@postman.riken.go.jp.

Published, JBC Papers in Press, June 19, 2000, DOI 10.1074/jbc.M001229200

    ABBREVIATIONS

The abbreviations used are: RANKL, receptor activator of NF-kappa B ligand; RANK, receptor activator of NF-kappa B; M-CSF, macrophage colony-stimulating factor; MAP, mitogen-activated protein; MKK, MAP kinase kinase; RT-PCR, reverse transcription-polymerase chain reaction; TRAF, tumor necrosis factor receptor-associated factor; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; OPG, osteoprotegerin; TRAP, tartrate-resistant acid phosphatase; NEAA, non-essential amino acid; GST, glutathione S-transferase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Ash, P., Loutit, J. F., and Townsend, K. M. (1980) Nature 283, 669-670
2. Scheven, B. A., Visser, J. W., and Nijweide, P. J. (1986) Nature 321, 79-81
3. Kurihara, N., Suda, T., Miura, Y., Nakauchi, H., Kodama, H., Hiura, K., Hakeda, Y., and Kumegawa, M. (1989) Blood 74, 1295-1302
4. Roodman, G. D. (1996) Endocr. Rev. 17, 308-332
5. Manolagas, S. C., and Jilka, R. L. N. (1995) N. Engl. J. Med. 332, 305-311
6. Hayashi, S., Yamane, T., Miyamoto, A., Hemmi, H., Tagaya, H., Tanio, Y., Kanda, H., Yamazaki, H., and Kunisada, T. (1998) Biochem. Cell Biol. 76, 911-922
7. Udagawa, N., Takahashi, N., Akatsu, T., Tanaka, H., Sasaki, T., Nishihara, T., Koga, T., Martin, T. J., and Suda, T. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7260-7264
8. Kurihara, N., Chenu, C., Miller, M., Civin, C., and Roodman, G. D. (1990) Endocrinology 126, 2733-2741
9. Takahashi, N., Udagawa, N., Tanaka, S., Murakami, H., Owan, I., Tamura, T., and Suda, T. (1994) Dev. Biol. 163, 212-221
10. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., Du Bose, R. F., Cosman, D., and Galibert, L. (1997) Nature 390, 175-179
11. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., and Suda, T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3597-3602
12. Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., 3rd, Frankel, W. N., Lee, S. Y., and Choi, Y. (1997) J. Biol. Chem. 272, 25190-25194
13. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. (1998) Cell 93, 165-176
14. Udagawa, N., Takahashi, N., Akatsu, T., Sasaki, T., Yamaguchi, A., Kodama, H., Martin, T. J., and Suda, T. (1989) Endocrinology 125, 1805-1813
15. Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., and Suda, T. (1988) Endocrinology 123, 2600-2602
16. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., and Penninger, J. M. (1999) Nature 397, 315-323
17. Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., Armstrong, A., Shen, V., Bain, S., Cosman, D., Anderson, D., Morrissey, P. J., Peschon, J. J., and Schuh, J. (1999) Genes Dev. 13, 2412-2424
18. Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H. L., Elliott, G., Kelley, M. J., Sarosi, I., Wang, L., Xia, X. Z., Elliott, R., Chiu, L., Black, T., Scully, S., Capparelli, C., Morony, S., Shimamoto, G., Bass, M. B., and Boyle, W. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3540-3545
19. Galibert, L., Tometsko, M. E., Anderson, D. M., Cosman, D., and Dougall, W. C. (1998) J. Biol. Chem. 273, 34120-34127
20. Wong, B. R., Josien, R., Lee, S. Y., Vologodskaia, M., Steinman, R. M., and Choi, Y. (1998) J. Biol. Chem. 273, 28355-28359
21. Darnay, B. G., Ni, J., Moore, P. A., and Aggarwal, B. B. (1999) J. Biol. Chem. 274, 724-731
22. Lomaga, M. A., Yeh, W. C., Sarosi, I., Duncan, G. S., Furlonger, C., Ho, A., Morony, S., Capparelli, C., Van, G., Kaufman, S., van der Heiden, A., Itie, A., Wakeham, A., Khoo, W., Sasaki, T., Cao, Z., Penninger, J. M., Paige, C. J., Lacey, D. L., Dunstan, C. R., Boyle, W. J., Goeddel, D. V., and Mak, T. W. (1999) Genes Dev. 13, 1015-1024
23. Naito, A., Azuma, S., Tanaka, S., Miyazaki, T., Takaki, S., Takatsu, K., Nakao, K., Nakamura, K., Katsuki, M., Yamamoto, T., and Inoue, J. (1999) Genes Cells 4, 353-362
24. Nishida, E., and Gotoh, Y. (1993) Trends Biochem. Sci. 18, 128-131
25. Avruch, J., Zhang, X. F., and Kyriakis, J. M. (1994) Trends Biochem. Sci. 19, 279-283
26. Davis, R. J. (1994) Trends Biochem. Sci. 19, 470-473
27. Iwasaki, S., Hattori, A., Sato, M., Tsujimoto, M., and Kohno, M. (1996) J. Biol. Chem. 271, 17360-17365
28. Iwasaki, S., Iguchi, M., Watanabe, K., Hoshino, R., Tsujimoto, M., and Kohno, M. (1999) J. Biol. Chem. 274, 26503-26510
29. Schwenger, P., Alpert, D., Skolnik, E. Y., and Vilcek, J. (1998) Mol. Cell. Biol. 18, 78-84
30. Cobb, M. H., and Goldsmith, E. J. (1995) J. Biol. Chem. 270, 14843-14846
31. Sudo, T., Maruyama, M., and Osada, H. (2000) Biochem. Biophys. Res. Commun. 269, 521-525
32. Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M. T., Martin, T. J., and Suda, T. (1999) J. Clin. Invest. 103, 1345-1352
33. Matsumoto, M., Tanaka, N., Harada, H., Kimura, T., Yokochi, T., Kitagawa, M., Schindler, C., and Taniguchi, T. (1999) Biol. Chem. 380, 699-703
34. Arai, F., Miyamoto, T., Ohneda, O., Inada, T., Sudo, T., Brasel, K., Miyata, T., Anderson, D. M., and Suda, T. (1999) J. Exp. Med. 190, 1741-1754
35. Takaoka, A., Tanaka, N., Mitani, Y., Miyazaki, T., Fujii, H., Sato, M., Kovarik, P., Decker, T., Schlessinger, J., and Taniguchi, T. (1997) EMBO J. 18, 2480-2488
36. Beyaert, R., Cuenda, A., Vanden Berghe, W., Plaisance, S., Lee, J. C., Haegeman, G., Cohen, P., and Fiers, W. (1996) EMBO J. 15, 1914-1923
37. Young, P. R., McLaughlin, M. M., Kumar, S., Kassis, S., Doyle, M. L., McNulty, D., Gallagher, T. F., Fisher, S., McDonnell, P. C., Carr, S. A., Huddleston, M. J., Seibel, G., Porter, T. G., Livi, G. P., Adams, J. L., and Lee, J. C. (1997) J. Biol. Chem. 272, 12116-12121
38. Kumar, S., Jiang, M. S., Adams, J. L., and Lee, J. C. (1999) Biochem. Biophys. Res. Commun. 263, 825-831
39. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., De Rose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R., and Boyle, W. J. (1997) Cell 89, 309-319
40. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Goto, M., Mochizuki, S., Suda, E., Morinaga, T., Udagawa, N., Takahashi, N., Suda, T., and Higashino, K. (1999) Bone 25, 109-113
41. Rajavashisth, T. B., Eng, R., Shadduck, R. K., Waheed, A., Ben-Avram, C. M., Shively, J. E., and Lusis, A. J. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 1157-1161
42. Sherr, C. (1990) Blood 75, 1-12
43. Hofstetter, W., Wetterwald, A., Cecchini, M. C., Felix, R., Fleisch, H., and Mueller, C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9637-9641
44. Tanaka, S., Takahashi, N., Udagawa, N., Tamura, T., Akatsu, T., Stanley, E. R., Kurokawa, T., and Suda, T. (1993) J. Clin. Invest. 91, 257-263
45. Akatsu, T., Takahashi, N., Debari, K., Morita, I., Murota, S., Nagata, N., Takatani, O., and Suda, T. (1989) J. Bone Miner Res. 4, 29-35
46. Abe, E., Miyaura, C., Tanaka, H., Shiina, Y., Kuribayashi, T., Suda, S., Nishii, Y., De Luca, H. F., and Suda, T. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 5583-5587
47. Akatsu, T., Takahashi, N., Udagawa, N., Sato, K., Nagata, N., Moseley, J. M., Martin, T. J., and Suda, T. (1989) Endocrinology 125, 20-27
48. Lagasse, E., and Weissman, I. L. (1997) Cell 89, 1021-1031
49. Hayashi, S., Miyamoto, A., Yamane, T., Kataoka, H., Ogawa, M., Sugawara, S., Nishikawa, S., Nishikawa, S., Sudo, T., Yamazaki, H., and Kunisada, T. (1997) J. Cell. Physiol. 170, 41-47
50. Jiang, Y., Chen, C., Li, Z., Guo, W., Gegner, J. A., Lin, S., and Han, J. (1996) J. Biol. Chem. 271, 17920-17926
51. Stein, B., Yang, M. X., Young, D. B., Janknecht, R., Hunter, T., Murray, B. W., and Barbosa, M. S. (1997) J. Biol. Chem. 272, 19509-19517
52. Lechner, C., Zahalka, M. A., Giot, J. F., Moller, N. P., and Ullrich, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4355-4359
53. Li, Z., Jiang, Y., Ulevitch, R. J., and Han, J. (1996) Biochem. Biophys. Res. Commun. 228, 334-340
54. Wang, X. S., Diener, K., Manthey, C. L., Wang, S., Rosenzweig, B., Bray, J., Delaney, J., Cole, C. N., Chan-Hui, P. Y., Mantlo, N., Lichenstein, H. S., Zukowski, M., and Yao, Z. (1997) J. Biol. Chem. 272, 23668-23674
55. Jiang, Y., Gram, H., Zhao, M., New, L., Gu, J., Feng, L., Di Padova, F., Ulevitch, R. J., and Han, J. (1997) J. Biol. Chem. 272, 30122-30128
56. Moriguchi, T., Toyoshima, F., Gotoh, Y., Iwamatsu, A., Irie, K., Mori, E., Kuroyanagi, N., Hagiwara, M., Matsumoto, K., and Nishida, E. (1996) J. Biol. Chem. 271, 26981-26988
57. Raingeaud, J., Whitmarsh, A. J., Barrett, T., Derijard, B., and Davis, R. J. (1996) Mol. Cell. Biol. 16, 1247-1255

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J EndocrinolHome page
N. Al-Shanti and C. E Stewart
PD98059 enhances C2 myoblast differentiation through p38 MAPK activation: a novel role for PD98059
J. Endocrinol., July 1, 2008; 198(1): 243 - 252.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. Duplomb, M. Baud'huin, C. Charrier, M. Berreur, V. Trichet, F. Blanchard, and D. Heymann
Interleukin-6 Inhibits Receptor Activator of Nuclear Factor {kappa}B Ligand-Induced Osteoclastogenesis by Diverting Cells into the Macrophage Lineage: Key Role of Serine727 Phosphorylation of Signal Transducer and Activator of Transcription 3
Endocrinology, July 1, 2008; 149(7): 3688 - 3697.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
T. Thalhamer, M. A. McGrath, and M. M. Harnett
MAPKs and their relevance to arthritis and inflammation
Rheumatology, April 1, 2008; 47(4): 409 - 414.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
H. J. Kim, Y. Lee, E.-J. Chang, H.-M. Kim, S.-P. Hong, Z. H. Lee, J. Ryu, and H.-H. Kim
Suppression of Osteoclastogenesis by N,N-Dimethyl-D-erythro-sphingosine: A Sphingosine Kinase Inhibition-Independent Action
Mol. Pharmacol., August 1, 2007; 72(2): 418 - 428.
[Abstract]